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Every known SWI/SNF chromatin-remodeling complex incorporates an ARID DNA binding domain-containing subunit. De-
spite being a ubiquitous component of the complex, physiological roles for this domain remain undefined. Here, we show that
disruption of ARID1a-DNA binding in mice results in embryonic lethality, with mutant embryos manifesting prominent defects
in the heart and extraembryonic vasculature. The DNA binding-defective mutant ARID1a subunit is stably expressed and capa-
ble of assembling into a SWI/SNF complex with core catalytic properties, but nucleosome substrate binding and promoter occu-
pancy by ARID1a-containing SWI/SNF complexes (BAF-A) are impaired. Depletion of ARID domain-dependent, BAF-A associa-
tions at THROMBOSPONDIN 1 (THBS1) led to the concomitant upregulation of this SWI/SNF target gene. Using a THBS1
promoter-reporter gene, we further show that BAF-A directly regulates THBS1 promoter activity in an ARID domain-dependent
manner. Our data not only demonstrate that ARID1a-DNA interactions are physiologically relevant in higher eukaryotes but
also indicate that these interactions facilitate SWI/SNF binding to target sites in vivo. These findings support the model wherein
cooperative interactions among intrinsic subunit-chromatin interaction domains and sequence-specific transcription factors
drive SWI/SNF recruitment.
The identification of DNase I-hypersensitive sites in active glo-bin genes was the first evidence linking nucleosome conforma-
tion to transcriptional activity (1). Insight into how nucleosome
conformation is controlled came from subsequent genetic studies
that identified yeast mutants unable to switch mating types (SWI)
or utilize sucrose as a carbon source (sucrose nonfermenter, or
SNF) (2, 3). It was later found the majority of swi/snf-encoded
proteins were components of a large, multiprotein complex (col-
lectively referred to as the SWI/SNF chromatin-remodeling com-
plex) that could utilize energy derived from ATP hydrolysis to
alter nucleosome conformation and thus modulate DNA accessi-
bility (4–6).
To remodel chromatin, the SWI/SNF complex must recognize
and bind its nucleosomal target substrates. This complex binds
DNA with high affinity, but the DNA binding domains responsi-
ble for mediating intrinsic subunit-DNA interactions bind with
little to no sequence specificity in vitro—a property that makes
them incompatible with a primary role in recruitment (7–14).
Current models implicate subunit interactions with sequence-
specific transcription factors in primary SWI/SNF recruitment
(15). The precise function of non-sequence-specific DNA binding
domains within SWI/SNF is currently unknown.
Of the DNA binding domains responsible for mediating non-
sequence-specific subunit-DNA interactions, the ARID domain is
noteworthy because all known SWI/SNF complexes incorporate a
subunit belonging to the ARID family of proteins. In addition, the
SWI/SNF complexes found in higher eukaryotes are known to
incorporate two or more mutually exclusive ARID subunits, with
each subunit representing a biochemically distinct complex sub-
family. In mammals, ARID2 (BAF200) embodies the PBAF com-
plex, while ARID1a (BAF250a) and the paralogous subunit
ARID1b (BAF250b) embody BAF-A and BAF-B complexes, re-
spectively (16–21). Additional evidence indicates that ARID sub-
unit usage influences transcription factor associations with these
complexes (22). These data are consistent with the notion that
ARID subunits can tailor their respective complexes for specific
roles (21, 22) although their exact contributions to SWI/SNF
function have not been established.
Currently, of the three known mammalian ARID subunits,
only ARID1a has been deemed essential. Homozygous Arid1a-
null embryos manifest an early block in germ layer formation
(23). ARID1a is also mutated in 50% of the ovarian clear cell
carcinomas and 30% of the endometrioid carcinomas found in
humans (24, 25). Since ARID1a-containing BAF-A complexes are
essential, we surmised that genetic approaches aimed at disrupt-
ing the ARID domain of ARID1a would allow us to determine
how ARID-DNA interactions contribute to SWI/SNF activity in
vivo.
To address this question, we screened an N-ethyl-N-nitrosurea
(ENU)-mutagenized mouse embryonic stem (ES) cell library for
point mutations in the region encoding the ARID domain of ARID1a
and isolated an ENU-induced mutation which leads to a valine-to-
glycine substitution at amino acid position 1068 (herein referred to as
V1068G). The mutant ARID1a protein is stably expressed, and it
incorporates into a BAF-A complex with core chromatin remodeling
function. However, its ability to bind DNA is severely impaired. Im-
paired ARID1a-DNA interactions result in a partial loss-of-function
or hypomorphic allele because homozygous mutant embryos gastru-
late and are recovered as late as embryonic day 13.5 (E13.5). Ho-
mozygous Arid1a embryos carrying the V1068G mutation
(Arid1aV1068G/V1068G) manifest heart defects, fail to establish proper
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extraembryonic vasculature, and exhibit hemorrhaging. As a result of
these phenotypes, Arid1aV1068G/V1068G embryos failed to establish
proper circulation, culminating in ischemic arrest in utero. We show
that disruption of ARID1a-DNA interactions reduces BAF-A affinity
for nucleosomes. Consistent with this, mutant BAF-A occupancy at
the known BAF-A target gene, THROMBOSPONDIN-1 (THBS1),
was impaired, resulting in THBS1 upregulation. Finally, we show that
BAF-A directly represses THBS1 promoter activity using luciferase
reporter assays. Our data demonstrate that the ARID domain of
ARID1a is essential for development and that ARID1a-DNA interac-
tions are required for promoter occupancy by SWI/SNF.
MATERIALS AND METHODS
Library screening, generation of the V1068G mutant allele, and mouse
husbandry. E14 and CT129 ENU-mutagenized ES cell libraries were gen-
erated as previously described (26, 27). RNA isolated from 96-well ES cell
libraries was reverse transcribed and used as the template for PCRs using
12 primer pairs spanning the mouse ARID1a cDNA (NCBI Reference
Sequence NM_001080819.1). A series of denaturation and slow annealing
cycles were performed to allow formation of heteroduplexes. Samples
were then analyzed by denaturing high-performance liquid chromatog-
raphy (dHPLC) using WAVE mutation detection software (Trans-
genomic). Screening temperatures were chosen based on analysis of the
melting curve for each PCR fragment. Following detection of a mutation
and confirmation by sequencing, cell lines were subcloned from a single
cell suspension and verified by dHPLC to ensure clonality of the muta-
tions. Karyotyping was performed to monitor the genomic integrity of
cells prior to injection. Cells were injected into C57BL/6 blastocysts and
implanted into pseudopregnant females. Germ line animals were detected
by coat color and PCR/HPLC confirmation of tail DNA samples. They
were then out-crossed onto a CD1 background for 10 generations. All
mice were maintained at the University of North Carolina at Chapel Hill
Animal Facility using standard techniques in accordance with protocols
approved by the University of North Carolina at Chapel Hill Institutional
Animal Care and Use Committee.
Genotyping. Arid1a/; Arid1aV1068G/; Arid1aV1068G/V1068G alleles
were genotyped by a HincII restriction fragment length polymorphism
induced by the T-to-G mutation (T is base 3203 in NCBI Reference Se-
quence NM_001080819.1) (Fig. 1A). Briefly, genomic DNAs harvested
from mouse embryos or tail samples from live-born mice were PCR am-
plified using standard techniques and the following primer set: forward
(F), 5=-GCCGTTTGAATTTGTCCTGT; reverse (R), 5=-TCTTGGGTTG
GGACTTCTTG. PCR products were subsequently digested with HincII
(NEB) and then resolved by 2% Tris-borate-EDTA agarose gel electro-
phoresis.
Cell culture and siRNA transfections. Arid1a/ and Arid1aV1068G/V1068G
mouse embryonic fibroblasts (MEFs) were isolated from E9.5 embryos
using standard procedures and cultured in Dulbecco’s modified Eagle
medium supplemented with 4.5 g/liter glucose, 2 mM sodium pyruvate,
0.5 g/liter L-glutamine, 15% fetal bovine serum, 200 units/liter penicillin
G, and 200 g/liter streptomycin sulfate. Low-passage primary MEFs were
transformed as previously described (28, 29). MEFs were transfected with
50 nM amounts of nontargeting (mock), BRG1, and BRM small interfer-
ing RNA (siRNA) smart pools (M-056591-00-005 and M-041135-01-
0005; Dharmacon) using 2.5 l/ml of RNAiMax transfection reagent (In-
vitrogen) according to the manufacturer’s instructions. BRG1 and BRM
depletion were verified by reverse transcription-PCR (RT-PCR) using
gene-specific primer sets (data not shown). Mouse NIH 3T3 and human
HEK 293T cells were cultured following ATCC standards.
Protein expression and DNA binding experiments. The glutathione
S-transferase (GST)–ARID protein fragments used in DNA binding ex-
periments are the products of GST-DRI258 – 410 (DRI258 – 410 is the region
of amino acids 258 to 410 encoded by the dead ringer gene, referred to as
GST-DriARID) (30) and GST-p270600 –1018 (GST fused to the region of
amino acids 600 to 1018 of human p270, referred to as GST-hARID) (16).
Valine-to-glycine amino acid substitutions were generated by PCR-based,
site-directed mutagenesis of the parent GST-ARID plasmids, followed by
FIG 1 Arid1aV1068G/V1068G embryos manifest neural tube and heart defects. Whole-mount images of E9.5 and 10.5 Arid1a/ (A and B) or Arid1aV1068G/V1068G
(G and H) littermate embryos are shown. E9.5 and E10.5 Arid1aV1068G/V1068G embryos display open head folds (G and H, arrowheads). E10.5 Arid1aV1068G/V1068G
hearts are grossly abnormal and appeared developmentally delayed (H, arrows). Transverse histological sections through the hindbrain region (I, asterisk) or base
of tail (J, asterisk) of E9.5 Arid1aV1068G/V1068G embryos indicate neural tube closure defects. Transverse paraffin sections of E9.5 (E and K) and E10.5 (F and L)
Arid1a/ and Arid1aV1068G/V1068G hearts are shown. Trabeculation defects are prominent in E9.5 Arid1aV1068G/V1068G hearts (K and L, arrowheads), and these
defects are present at E10.5. Mutant E10.5 hearts (L) have hypoplastic myocardial walls and severe ventricular septal defects. v, ventricles; a, atria; vs, ventricular
septum.
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blunt-ended circularization, using the following 5= phosphorylated prim-
ers: GST-DRI258-410 F, 5=-(Phos)-GGCTTGGTGGATGGCATCAACAA
GAA, and R, 5=-(Phos)-GCCGCGGGCTATCACCAGATTGTACAG;
GST-p270600-1018 F, 5=-(Phos)-GATTGACTCAGGGCAACAAGAACAA,
and R, 5=-(Phos)-CACCAATCTCCTTCACAGACACATAGAG. GST-
DRI258-410 and GST-p270600-1018 proteins were expressed in Escherichia
coli NEB Express (New England BioLabs) and Rosetta-2 (Merck) strains,
respectively, and then purified essentially as previously described (31).
Binding conditions for gel mobility shift assays were as previously
described (19, 32). Binding isotherms were estimated by varying the pro-
tein concentrations by 2-fold dilutions (from 2 M to 0.48 nM). 32P-end-
labeled, double-stranded DNA probe at 50 pM was used per binding re-
action. Forward sequences of the oligonucleotide probes used in the
binding reactions are as follows: dri.16, 5=-CATCAATAAATTAGAAT
TAA; p270.18, ACCGGGGGTGCCACACCGTTGA (16). GST-DriARID-
DNA complexes were resolved by 8% Tris-borate-EDTA acrylamide elec-
trophoresis, and GST-hARID-DNA complexes were resolved by 8% Tris-
acetate-EDTA (pH 7.8) acrylamide electrophoresis. Gels were dried and
then imaged using a PhosphorImager (Molecular Dynamics, Inc.). Frac-
tional occupancies were calculated from band densitometry measure-
ments using the following formula: 1  (DNAfree/DNAtotal).
Western blotting. Western blotting was performed using standard
procedures and the following antibodies: ARID1a (A301-040A or A301-
041A; Bethyl Labs), ARID1b (sc-32762; Santa Cruz), ARID2 (A302-230A;
Bethyl Labs), BRG1 (sc-17796; Santa Cruz), BRM (sc-6450; Santa Cruz),
INI1/SNF5 (A301-087A; Bethyl Labs), BAF60a (611728; BD Biosciences),
cullin-2 (ab1870; Abcam), THBS-1 (MS-421-P0; Thermo Scientific),
hemagglutinin (HA) tag (A190-108A; Bethyl Labs), -actin (ab8226;
Abcam), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Sigma),
and nucleolin (A300-711A; Bethyl Labs). Primary antibodies were de-
tected using goat anti-rabbit, goat anti-mouse, or donkey anti-goat sec-
ondary antibodies conjugated to horseradish peroxidase (Santa Cruz).
For fluorescent Western blot detection, Li-COR Bioscience Odyssey
blocking buffer and fluorescent secondary antibodies were used according
to the manufacturer’s instructions.
Coimmunoprecipitations and immunoaffinity isolation of ARID1a-
containing complexes. Small-scale nuclear extracts used in immunopre-
cipitations were prepared from wild-type or Arid1aV1068G/V1068G MEFs as
previously described (33, 34). Briefly, nuclear proteins were extracted
from isolated nuclei with two sequential 30-min incubations in 0.6 vol-
umes (per semidry cell pellet) of buffer C (20 mM HEPES-KOH [pH 7.9],
0.2 mM EDTA, 25% glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.5 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, mammalian pro-
tease inhibitor cocktail) at 4°C. The final salt concentration of nuclear
extracts was lowered to approximately 150 mM KCl by the addition of
KCl-free buffer C. Nuclear extracts were clarified by centrifugation, snap
frozen in liquid nitrogen, and then stored at 80°C. Antibodies specific
for BRG1 (sc-10768; Santa Cruz) and BRM (ab15597; Abcam) or ARID1a
(sc-32761; Santa Cruz) were preconjugated to bovine serum albumin
(BSA)-blocked protein A/G-agarose (Santa Cruz). Immunoprecipita-
tions (IPs) were performed in IP buffer (20 mM HEPES-KOH [pH 7.9],
0.2 mM EDTA, 10% glycerol, 0.1% Tween 20, 0.5 mM dithiothreitol, 0.5
mM phenylmethylsulfonyl fluoride, mammalian protease inhibitor cock-
tail) supplemented with 150 mM KCl using 600 g of precleared nuclear
extracts. Immunoprecipitates were washed seven times with 20 volumes
of IP buffer supplemented with 500 mM KCl. To lower the final salt
concentration, the last wash was performed with IP buffer supplemented
with 100 mM KCl. The immunoprecipitates were eluted with acidic gly-
cine, and then the eluates were neutralized with 0.1 volumes of 1 M
Tris-Cl (pH 8.0). The final eluates were resolved by SDS-PAGE and ana-
lyzed by Western blotting. For immunoaffinity isolation of ARID1a-con-
taining complexes, the washed agarose bead–anti-ARID1a immune con-
jugates from above were equilibrated in IP buffer supplemented with 60
mM KCl following the last 100 mM KCl wash and used immediately or
stored at 4°C. Similar high-salt immunopurification methods have been
used to isolate SWI/SNF complexes from mammalian cells (35).
REA. Restriction enzyme accessibility (REA) assays were per-
formed as previously described (36). A mononucleosome-positioning
DNA fragment from the pTPT plasmid (37) was radiolabeled with
[32P]dCTP by PCR using the following primers: F, ACGCGTCGGT
GTTAGAGC, and R, GAATTCTCTAGACAGTGTCCCA. Mononucleo-
somes were assembled according to the “salt jump” method (38, 39) in the
presence of core histones from HeLa cells and sonicated calf thymus car-
rier DNA. Crude mononucleosome assemblies were gel fractionated by
5% Tris-EDTA (pH 7.6) acrylamide electrophoresis and then gel purified
by diffusion in 10 mM Tris-Cl (pH 7.6), 0.2 mM EDTA, 40 mM NaCl,
0.01% Igepal CA-380, and 0.5 mM phenylmethylsulfonyl fluoride at 4°C
for 12 to 18 h. Mononucleosome assemblies were concentrated and then
stored at 4°C in gel elution buffer supplemented with 15% glycerol, 0.3
mg/ml bovine serum albumin (BSA), 0.1% Igepal CA-380, and 1 mM
dithiothreitol. Mononucleosomes were incubated at 37°C for 15 min
prior to use. Gel-purified mononucleosomes (1 nM) were incubated
with either 2 mM ATP or ATPS and saturating amounts of immunoaf-
finity-purified ARID1a-containing complexes on beads in a 20-l reac-
tion mixture containing 12 mM HEPES-KOH (pH 7.9), 2 mM Tris-Cl
(pH 7.6), 60 mM KCl, 8 mM NaCl, 4 mM MgCl2, 0.2 mM dithiothreitol,
0.06 mg/ml bovine serum albumin (BSA), 0.02% Igepal CA-380, 3% glyc-
erol, and 0.5 unit/l PstI enzyme (NEB) for 10, 20, 30, or 40 min at 30°C.
Reactions were quenched by the addition of 1.5 volumes (30 l) of 20 mM
Tris-Cl (pH 7.6), 50 mM EDTA, 2% SDS, 0.2 mg/ml proteinase K, and
0.75 mg/ml yeast tRNA (from Saccharomyces cerevisiae), followed by a 1-h
incubation at 55°C. Samples were ethanol precipitated and resolved by 6%
Tris-borate-EDTA acrylamide electrophoresis. Gels were dried and then
exposed to film. Band densitometry measurements from triplicate sam-
ples containing independent preparations of BAF-A complexes were av-
eraged, and the standard deviations of the triplicate values measured were
plotted. Statistical differences were detected using a two-tailed Student t
test.
Nucleosome pulldown assays. Saturating amounts of immunoaffin-
ity-purified ARID1a-containing, BAF-A complexes on beads were incu-
bated with the internally labeled and gel-purified TPT mononucleosomes
(1 nM) from the procedure described above in a 20-l reaction mixture
containing 12 mM HEPES-KOH (pH 7.9), 2 mM Tris-Cl (pH 7.6), 60 mM
KCl, 8 mM NaCl, 4 mM MgCl2, 0.2 mM dithiothreitol, 0.06 mg/ml bovine
serum albumin (BSA), 0.02% Igepal CA-380, and 3% glycerol supple-
mented with 1.6 to 50 ng (from 2-fold dilutions) of sheared salmon sperm
DNA for 30 min at 30°C. The competitor DNA titration range was deter-
mined in a previous experiment (data not shown). Beads containing
nucleosome-bound BAF-A complexes were washed three times with 25
volumes of binding buffer to remove unbound nucleosomes, and the
bound fractions were eluted by the addition of 1.5 volumes (30 l) of 20
mM Tris-Cl (pH 7.6), 50 mM EDTA, 2% SDS, 0.2 mg/ml proteinase K,
and 0.75 mg/ml yeast tRNA, followed by a 1-h incubation at 55°C. Sam-
ples were ethanol precipitated and resuspended in H2O. Each pulldown
condition was performed in triplicate using independent preparations of
BAF-A complexes. Independent samples were subjected to scintillation
counting (as cpm) or resolved by 6% Tris-borate-EDTA acrylamide elec-
trophoresis. Average cpm values and the standard deviations of the trip-
licate values measured were plotted. Statistical differences were detected
using a two-tailed Student t test.
ChIP. Wild-type or Arid1aV1068G/V1068G MEFs were fixed in growth
medium containing formaldehyde for 10 min at room temperature, and
the formaldehyde-cross-linked chromatin extracts were prepared as pre-
viously described (40). Cross-linked chromatin was sonicated on ice to an
average DNA length between 300 and 700 bp in 10 mM Tris-Cl (pH 8.0),
1 mM EDTA, and 0.5 mM EGTA. Precleared chromatin (300 g) was
incubated with 5 g of ARID1a (sc-32761; Santa Cruz), ARID1b (sc-
32762; Santa Cruz), ARID2 (sc-98299; Santa Cruz), BRG1 (sc-10768;
Santa Cruz), BRM (sc-6450; Santa Cruz), INI1/SNF5 (A301-087A; Bethyl
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Labs), or polymerase II (Pol II) (sc-899; Santa Cruz) antibodies in 1 ml of
chromatin immunoprecipitation (ChIP) buffer (50 mM Tris-Cl [pH 7.6],
150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA-380, 1% TX-100) (41)
overnight at 4°C. Salmon sperm DNA-blocked protein A/G-agarose beads
(Santa Cruz) were added for 3 h at 4°C, and then the agarose bead-anti-
ARID1a immune conjugates were washed eight times with 20 volumes of
ChIP buffer supplemented with 500 mM NaCl, followed by a final wash in
low-salt TE buffer (10 mM Tris-Cl [pH 8.0], 1 mM EDTA, 50 mM NaCl).
DNA was eluted, and cross-links were reversed by the addition of a 10%
Chelex-100 –H2O slurry (Bio-Rad) and a 15-min incubation at 95°C. Pro-
tein was digested with 20 g/ml proteinase K at 55°C for 1 h. Real-time
quantitative PCR using Ssofast PCR master mix (Bio-Rad) and a CFX96
thermocycler (Bio-Rad) was performed using the following gene-specific
primers: for THBS1 3.0 kb, TCTGAGCCCTCCAGAGGTAA and TCT
GTTGCTCAGGACTGTGG; THBS1 1.4 kb, CAAGAGGCACTGGCTG
TGTA and CTTGTGTGGGAGGGAGTGTT; THBS1 1.2 kb, GGATCC
CTGGACTCAGAGC and GCTGCCTGATCCTTTGTCTC; THBS1 0.4
kb, ACCCACCAGGATTGACTCAG and TTCCATGACAGAGACGC
TTG; THBS1 transcription start site (TSS), TTAAAAGGTCCTGGGC
TCCT and GAAGGACAAGGACGCTGAGT; THBS1 1.0 kb, GCTCCT
CACAGCCAGAACTT and TAGATCTTGGCCCTTCACCA; THBS1
down, TGTCTGTCTTCACGGGGTTA and TGGCTTCAGCCTATTCC
TTG; ADAMTS1, CGTCACTCTGGGGGTGTAAG and CACTCTTTTC
CCCAGAGCAG; CRABP1, CCAGGGGAGAGCAAGTTCC and CTTGA
GTCGCTAGGGTAG; GAPDH (control), GGAAGCAGCATTCAGGT
CTCT and CCTCCTCCCTCTCTTTGGAC; INSULIN (control), TGGA
TGCCCACCAGCTTTATAGTCC and AACTGGTTCATCAGGCCATC
TGGTC. Data from three independent experiments were averaged and
plotted as a percentage of the total input 	 standard error of the mean
(SEM; adjusted for a 50-fold input dilution). Statistical differences were
detected using a two-tailed Student t test.
RT-PCR. To analyze target gene transcript levels in wild-type or
Arid1aV1068G/V1068G MEFs, total RNA was extracted using the TRIzol
method (Invitrogen), followed by an RNA cleanup step and on-column
DNA digestion using an RNeasy miniprep kit (Qiagen) according to the
manufacturer’s instructions. cDNA was prepared using Multiscribe re-
verse transcriptase (Applied Biosystems) and a random primer mix
(NEB). Real-time quantitative PCR using Ssofast PCR master mix (Bio-
Rad) and a CFX96 thermocycler (Bio-Rad) was performed using the fol-
lowing gene-specific primers: for THBS1, CATCTTTGAACTCATTGG
and TAGGTCTTGGAACTTGTC; ADAMTS1, TACTCTGGCACGGT
GAAC and ATGAAGAACTCCTCTCCTTGTAG; CRABP1, AATGAGAA
CAAGATTCACT and GCCAAATGTCAGGATTAG; BRG1, GCTTCTTT
GTTTCCTGAG and TCTGGAGTAGACATCTTTAC; BRM, CTGATAA
CGAGTGACCAT and TAGATGACAATGAGGACG; -actin gene
(control), CGAGCGTGGCTACAGCTTCACC and CCGATCCACACAG
AGTACTTGCG. Expression was calculated from three independent ex-
periments using 
CT (where CT is threshold cycle) or 

CT methods.
Expression levels were normalized to the -actin gene. Statistical differ-
ences were detected using a two-tailed Student t test.
In situ hybridization and immunostaining. In situ hybridizations
and histology were performed exactly as previously described (42) using a
probe specific for Peg1 (43). Whole-mount immunostaining for platelet
endothelial cell adhesion molecule 1 (PECAM1; also CD-31) was per-
formed as described using a monoclonal rat anti-mouse CD31 antibody
(MEC13.3; BD Biosciences) (44). For direct THBS1 immunostaining of
slides, embryos were fixed in 10% neutral buffered formalin (Sigma),
washed in 1 phosphate-buffered saline (PBS), and then cryo-protected
through a graded sucrose series. Specimens were then embedded on dry
ice. Samples were sectioned at 12 m and collected on Superfrost-Plus
slides (Fisher). Frozen sections were briefly thawed on a 42°C slide
warmer, equilibrated in 1 PBS, and then incubated for 45 min in 100
mM glycine and 1 PBS (pH 7.3). Block and antibody diluent consisted
of 1 PBS– 0.05% Tween 20 supplemented with 5% donkey serum (Jack-
son ImmunoResearch), 1% (wt/vol) BSA, and 0.1% (wt/vol) cold-water
fish gelatin (Sigma). Slides were incubated in a 1:25 dilution of goat anti-
THBS1 antibody (sc-12312; Santa Cruz Biotechnology), followed by de-
tection with a species-specific fluorescent secondary antibody raised in
donkey. Slides were mounted and coverslipped in 4=,6=-diamidino-2-
phenylindole (DAPI)-containing Prolong-Gold medium (Invitrogen).
Construction of N-terminally HA-tagged ARID1a expression plas-
mids. To construct the HA-tagged mouse ARID1a expression plasmids,
we used a PCR-based strategy to clone ARID1a (isoform 2) from wild-
type or Arid1aV1068G/V1068G MEFs. mRNA was reverse transcribed using
Superscript III (Invitrogen), and the resulting cDNA was PCR amplified
using Phusion ultra-high-fidelity polymerase (NEB) and the following
primer set: F, ATGGATCAGATGGGAAAGATGAGACCTCAGC; R, TC
ATGACTGGCCAATCAAAAACAGTACATCACA (the start codon is un-
derlined). The PCR products were gel purified and blunt cloned into the
JET1.2 plasmid (Fermentas). Cloned cDNA inserts were extensively ver-
ified by sequencing. XhoI/SalI-digested cDNA fragments were ligated into
the pcDNA3.1() expression plasmid (Invitrogen) so that a single hem-
agglutinin (HA) tag was fused to the N termini of wild-type and mutant
ARID1a proteins using a GGS amino acid linker. Recombinant protein
expression was verified by plasmid transfection into HEK 293T cells and
by Western blotting using an anti-HA antibody (data not shown).
THBS1 promoter-luciferase assays. The mouse THBS1 2.8 kb pro-
moter-luciferase reporter plasmid (plasmid 12409; Addgene) has been
previously described (45). The THBS1 0.48 kb THBS1 promoter-lu-
ciferase plasmid was constructed by BamHI digestion and recirculariza-
tion of the THBS1 2.8 kb promoter-luciferase plasmid. The parental
pXP1 luciferase reporter plasmid was used as a negative control. NIH 3T3
cells at 50 to 60% confluence were transfected with 0.5 g of reporter
plasmid and 0 to 0.5 g of wild-type or mutant HA-tagged mouse ARID1a
(HA-mARID1a) expression plasmids using TransIT-2020 reagent (Mirus
Bio) according to the manufacturer’s instructions. The empty pcDNA3.1
expression plasmid was used as carrier DNA to bring the final DNA con-
centration to 0.5 g or as a negative control. Transfections were normal-
ized for efficiency using 2 ng of Renilla luciferase plasmid. Cells were
harvested 48 h after transfection, and reporter activity was measured using
a Dual Luciferase assay system (Promega) according to the manufactur-
er’s instructions. Normalized luciferase measurements from triplicate
transfections were averaged, and the standard deviations of the triplicate
values measured were plotted. Statistical differences were detected using a
two-tailed Student t test.
Microscopy, imaging, and bioinformatics. Histological sections were
analyzed and photographed on an Olympus BX51 microscope using
bright-field optics and a DP series digital camera (Olympus). Whole-
mount embryo and yolk sac specimens were imaged on a Leica MZ FLIII
stereomicroscope using a DS Ri1 digital camera (Nikon). Fluorescence
microscopy and image acquisition were performed using a Leica DM LB
microscope and a Retiga-2000R digital camera (Q-Imaging). Virtual pro-
tein mutagenesis was performed using the MuSE virtual mutation module
of PROTMAN software (46). Protein structures were rendered and visu-
alized using PyMol software (Schrodinger, LLC). KaleidoGraph software
(Synergy) was used for curve-fitting the electrophoretic mobility shift
assay (EMSA) binding isotherms. Comparative genome analysis was per-
formed using VISTA algorithms (47).
RESULTS
An ENU mutagenesis screen in mouse ES cells identifies a novel
Arid1a hypomorphic allele. To determine if ARID subunit-
DNA interactions have essential roles in higher eukaryotes, we
chose a phenotype-driven, ENU chemical mutagenesis strategy
to isolate critical point mutations in the ARID domain of
ARID1a. We screened our existing ENU-mutagenized mouse
ES cell libraries for point mutations within this domain (26, 27,
48). Mutations were identified by heteroduplex detection using
high-performance liquid chromatography (dHPLC). Two of
the three missense mutations identified within the ARID cod-
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ing region of ARID1a were transmitted through the germ line.
The first mutation (T to A) resulted in a cysteine-to-serine
substitution at amino acid 1100 (C1100S), while the second
mutation (T to G) resulted in a nonconservative, valine-to-
glycine substitution at amino acid 1068 (V1068G) in ARID1a
(NP_001074288). Homozygous C1100S mice were phenotypi-
cally normal at weaning. Arid1aV1068G/ mice on an outbred
(CD1) background were also phenotypically normal at this
stage. However, live-born Arid1aV1068G/V1068G offspring were
not recovered from crosses between heterozygous mice,
indicating that the V1068G mutation results in homozygous
lethality.
To determine the timing of lethality in utero, embryos were col-
lected at embryonic time points from crosses between heterozygous
mice and genotyped. At E8.5, Arid1aV1068G/V1068G embryos were re-
covered with Arid1aV1068G/ and Arid1a/ littermate offspring at
normal Mendelian ratios (data not shown). At time points beyond
E13.5, only Arid1aV1068G/ and Arid1a/ embryos were recovered.
Table 1 demonstrates that Arid1aV1068G/V1068G embryos were rou-
tinely recovered at E9.5, and of those recovered, fewer than half of
them (16%) lacked beating hearts. Beyond E10.5, the majority of
these mutant embryos were either dead or exhibited abated pulse
rates based upon visual inspection, and the number of resorbed em-
bryos observed in litters collected at these later time points tended to
increase with age. Since Arid1aV1068G/V1068G embryos arrest much
later in development than Arid1a-null embryos (23), this mutation
manifests as a hypomorphic allele.
Arid1aV1068G/V1068G embryos are grossly abnormal and de-
velopmentally delayed at midgestation. Arid1aV1068G/V1068G em-
bryos died around midgestation. These mutant embryos are
grossly indistinguishable from their wild-type littermates prior to
E8.5, and their allantoic buds and early somites are visible (data
not shown). At later time points, most mutant embryos are
smaller and display gross abnormalities, but the overall presenta-
tion of their body axes is appropriate for their respective develop-
mental stage as embryo turning and the associated inversion of
germ layers appear to occur normally (Fig. 1G and H). Mutant
embryos can be readily identified upon dissection by their open
neural tubes starting around E9.0 (Fig. 1G and H, arrowheads).
Failure of neural tube closure was consistently observed in the
hindbrain region and, to a lesser extent, in a posterior region near
the base of the tail (Fig. 1I and J, asterisks). Mutants also had small
optic cups and forebrains compared to the wild type at E9.5 (Fig.
1G). In spite of their slightly reduced size and these overt defects,
several aspects of embryonic development appear to proceed nor-
mally in Arid1aV1068G/V1068G embryos, such as the formation of
otic placodes and branchial arches. However, by E10.5, most mu-
tant embryos were clearly developmentally delayed, often resem-
bling those collected at E9.5 in appearance and by limb bud stag-
ing criteria (Fig. 1H). This delay is strikingly evident in E10.5
mutant hearts, which appear grossly immature compared to those
of the wild type (Fig. 1H, arrows). Beyond E10.5, pericardial effu-
sion was noted in some mutants, further indicating defects in
heart function at these later stages. Hemorrhaging was also ob-
served in the pericardial sac and abdomens of a few E11.5 mutant
embryos. These gross phenotypes are consistent with develop-
mental arrest between E9.0 and 10.5.
Heart defects are associated with the V1068G mutation. Our
gross inspection of whole-mount specimens indicated that heart
maturation was defective in mutant embryos. To examine these
defects in greater detail, histological sections harvested from E9.5
and E10.5 mutant hearts were compared to similar sections from
littermate controls. At E9.5, mutant hearts lacked ventricular tra-
beculation, and these defects persisted in E10.5 ventricles (Fig. 1K
and L, arrowheads). By E10.5, ventricular septal defects were ob-
vious in mutant hearts, indicating a block in cardiac chamber
maturation (Fig. 1L). These heart defects bear a striking resem-
blance to those observed in heterozygous Arid1a-null embryos
and in embryos completely lacking ARID1a in second heart field
(SHF) derivatives (via Mef2c-AHF-Cre), which further supports a
role for ARID1a-containing BAF-A complexes in cardiac progen-
itor differentiation (23, 49). In spite of these similarities, our data
suggest that the midgestation lethality observed in Arid1aV1068G/
V1068G embryos is due to the culmination of defects in multiple
tissues because SHF-specific loss of ARID1a in the heart results in
embryonic lethality at later time points (49).
ARID1a-containing BAF-A complexes are required for vas-
cular branching and vessel integrity in the extraembryonic yolk
sac and placenta. Embryo viability beyond E10.5 is known to be
critically dependent on proper extraembryonic circulation (50).
This dependence, coupled with our recent findings demonstrating
yolk sac angiogenic remodeling defects in Brg1fl/fl; Tie2-Cre/0
embryos, led us to examine this tissue in greater detail (44, 51).
Indeed, the yolk sacs of Arid1aV1068G/V1068G embryos were always
abnormal in comparison to those of littermate controls. Evidence
of hemorrhaging in the exocoelomic space was frequently ob-
served in these individuals starting as early as E9.5 (Fig. 2E, arrow-
head). The extent of blood loss observed varied from a few patchy
spots to large pools of blood. By E10.5, wild-type yolk sacs dis-
played a hierarchical, branch-like pattern of vessels, whereas mu-
tant yolk sac vasculature was poorly developed, often resembling
an immature, primary plexus consisting of small capillaries and
very few large, vitelline vessels (Fig. 2B and F). A scarcity of large
vessels coupled with blood loss also contributed to a frequently
observed pallor of mutant yolk sacs upon dissection. In spite of
these prominent yolk sac vascular defects, primitive hematopoie-
sis and flow patterns must have been established in mutants be-
cause nucleated, fetal blood can be visualized throughout the em-
bryo proper and yolk sac or pooled in the extraembryonic voids.
Furthermore, these primitive fetal blood cells most likely origi-
nated from the yolk sac because definitive erythropoiesis in em-
bryonic livers does not initiate until around E11.5. Overall, the
presentation of these phenotypes as early as E9.5 indicates that
yolk sac vascular dysfunction greatly contributes to mutant em-
bryo mortality.
Improper placental development also leads to death around
midgestation in mice (50). Development of the placenta ensues
shortly after the attachment of allantois to the chorion around
E8.5. Chorioallantoic attachment and subsequent formation of
the umbilical cord take place at these early stages in mutants (data








Lethality (%) (lethality 
resorption [%])
9.5 32 (5) 4 16 (25)
10.5 18 (7) 4 39 (50)
11.5 10 (8) 4 80 (86)
12.5 1 (1) 9 100
13.5 2 (2) 6 100
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not shown). At later stages, the trophoblast layers of mutant pla-
centas were discernible by histology, often having thick spong-
iotrophoblast layers (Fig. 2G, arrowheads). In general, mutant
placentas also appeared smaller than their wild-type counterparts,
despite having large maternal lacunae. The extent of vasculariza-
tion in both mutant and wild-type placentas was determined by
the expression of the extraembryonic mesoderm marker, Peg1
(Fig. 2D and H) (43). Vascular density was reduced, and minimal
branching was observed in E10.5 mutant placentas (Fig. 2H, ar-
rowheads). Specifically, the parental vessels appear to elongate
and bifurcate, but smaller, capillary-like vessels were scarce. This
reduction in vascular branching indicates that fetal-maternal ex-
change is defective in V1068G mutants. Therefore, proper extra-
embryonic vascular development requires normal BAF-A com-
plex function.
Mutant protein is stably expressed, and it incorporates into a
SWI/SNF complex with core catalytic function. ARID domains
do not appear to be required for complex integrity, nor do they ap-
pear to be required for the core catalytic properties of the complex
(52, 53). However, point mutations like V1068G could influence pro-
tein stability and/or conformation, leading to loss of multiple inter-
action surfaces. The presence of normal ARID1a protein levels in
mutant E9.5 whole-embryo lysates indicates that this point mutation
does not influence mutant protein expression and/or stability (Fig.
3A). We extended our analysis of potential subunit expression differ-
ences in wild-type versus Arid1aV1068G/V1068G E9.5 embryos by quan-
titative Western blotting using antibodies that recognize the alterna-
tive ARID subunits ARID1b and ARID2, the catalytic subunits
BRG1 and BRM, and the accessory subunits INI1/SNF5 and
BAF60a. Significant differences in subunit expression were not de-
tected when age-matched, whole-embryo protein lysates from
Arid1aV1068G/V1068G embryos were compared to those of the wild type
(Fig. 3A).
In order to determine if the endogenous mutant protein still
incorporates into the SWI/SNF complex, immunoprecipitations
were performed using antibodies that precipitate either ARID1a
or the catalytic subunits, BRG1 and BRM (Fig. 3B to D). These
experiments were performed using native nuclear extracts from
either wild-type or Arid1aV1068G/V1068G mouse embryonic fibro-
blasts (MEFs). Since an ARID1a-specific antibody is capable of
precipitating BRG1 and BRM, as well as the accessory subunits
BAF60a and INI1/SNF5, complex integrity does not appear to be
affected by the V1068G substitution in ARID1a (Fig. 3B and D). In
reciprocal immunoprecipitations using antibodies that precipi-
tate either BRG1 or BRM, we further corroborated the interac-
tions with ARID1a and BAF60a (Fig. 3C). We extended our anal-
ysis to include a noncanonical ARID1a-interaction partner,
cullin-2, which can also form stable interactions with mutant
ARID1a (Fig. 3E) (54). Together, these findings suggest that the
V1068G mutation does not influence the ability of ARID1a to
stably associate with canonical SWI/SNF subunits or noncanoni-
cal interaction partners.
To determine if mutant ARID1a-containing, BAF-A com-
plexes still maintain core catalytic function, we subjected recon-
stituted mononucleosomes to a PstI restriction enzyme accessibil-
ity assay in the presence of wild-type or mutant immunopurified
BAF-A complexes with either ATP or the nonhydrolyzable analog,
ATPS (36). Reactions were performed using saturating amounts
of immobilized BAF-A complexes (on beads), and the rates of PstI
site exposure were examined over a 40-min time course, with sam-
FIG 2 Prominent extraembryonic vascular abnormalities are present in Arid1aV1068G/V1068G concepti. Whole-mount images of E9.5 Arid1a/ (A) and
Arid1aV1068G/V1068G (E) yolk sacs are shown. Blood pools in the exocoelomic space of Arid1aV1068G/V1068G (E, arrowhead) are indicative of hemorrhaging.
Whole-mount PECAM staining of E10.5 Arid1a/ (B) and Arid1aV1068G/V1068G (F) yolk sacs was performed. Hierarchical vascular branching patterns are
evident in wild-type yolk sacs (B, arrowhead), whereas highly branched large vessels are scarce in mutant yolk sacs (F, arrowhead). Hematoxylin- and eosin-
stained paraffin sections of E10.5 Arid1a/ (C) and Arid1aV1068G/V1068G (G) placentas are shown. False-colored, yellow shading identifies the placenta. Proximal
(P) to distal (D) placental axes are demarcated by brackets. Mutant placentas display thick spongiotrophoblast layers (G, arrowheads). Near-adjacent paraffin
sections of E10.5 Arid1a/ (D) and Arid1aV1068G/V1068G (H) placentas hybridized with the pan-mesodermal marker Peg1 are shown. Vascular branching is
reduced in mutant placentas (H, arrowheads).
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ples quenched every 10 min. Both wild-type and mutant ARID1a-
containing complexes increased the rate of PstI site exposure to
similar extents with approximately half of the nucleosome parti-
cles undergoing remodeler-dependent cleavage after 20 min, sug-
gesting that these complexes are catalytically active in the presence
of ATP (Fig. 3F, lanes 5 and 11). Importantly, BAF-A-dependent
PstI site-accessible fractions were not observed in reaction mix-
tures containing mock-purified samples (Fig. 3F, lanes 3 and 9) or
ATPS (lanes 8 to 14). These findings are reminiscent of the intact
core catalytic activities of yeast SWI/SNF complexes lacking an
ARID domain (53). Altogether, these data strongly suggest that
BAF-A complex integrity and core catalytic properties are unaf-
fected by the V1068G mutation within the ARID domain of
ARID1a.
The V1068G mutation abrogates ARID-DNA binding. The
lethal phenotypes observed in Arid1aV1068G/V1068G embryos dem-
onstrate that the V1068 residue is critical for normal ARID1a
function. In general, critical protein residues are likely to be con-
served throughout evolution. Based on primary sequence homol-
ogy, the minimal ARID domain of ARID1a is phylogenetically
similar to the Drosophila melanogaster Retained/Dri (Retn/Dri)
and Mus musculus ARID3a/BRIGHT minimal ARIDs (55). The
mutated valine (V1068) residue (Fig. 4A, red) is conserved among
all ARID proteins belonging to the Dri/BRIGHT clade, including
FIG 3 The V1068G mutation does not affect the stability or the catalytic activity of BAF-A complexes. (A) Quantitative fluorescent Western blots (WB) of
Arid1a/ and Arid1aV1068G/V1068G E9.5 whole-embryo lysates probed with SWI/SNF subunit-specific antibodies. Graph represents the average 	 SEM of the
normalized band intensity from three age- or littermate-matched whole-embryo lysates. Band intensity measurements are plotted as a ratio to -actin signals,
and wild-type (wt) measurements were set at 1. mut, mutant. (B to E) Coimmunoprecipitation of SWI/SNF complex subunits or cullin-2 from wild-type or
Arid1aV1068G/V1068G MEFs. Shown are Western blot panels containing input protein, mock-precipitated (protein A/G-agarose bead only) protein, or protein
precipitated with antibodies specific for ARID1a, BRG1, or BRM. Western blots were probed with antibodies specific for ARID1a, BRG1, BRM, INI1/SNF5,
BAF60a, and cullin-2. (F) Mononucleosome disruption by wild-type and mutant ARID1a-containing complexes increases PstI restriction site exposure. Fixed
amounts of anti-ARID1a immunopurified fractions from either wild-type or Arid1aV1068G/V1068G MEFs were incubated with limiting amounts of gel-purified,
radiolabeled mononucleosomes over a 40-min time course in the presence of ATP. Reaction mixtures containing wild-type or mutant anti-ARID1a fractions
were quenched at 10-min intervals. Reaction mixtures containing ATPS or mock-purified (protein A/G-agarose bead only) fractions and incubated over the
entire time course served as controls. Naked DNA (lane 1) or mononucleosomes (lane 2) incubated without immunopurified material are shown. Uncut
fractions were plotted as a ratio of the total DNA. Error bars in panel F represent the standard deviations, and significant differences were calculated using a
two-tailed Student t test (*, P  0.05).
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the D. melanogaster and Saccharomyces cerevisiae putative ARID1a
homologs, Osa and SWI1, respectively. This residue is also invari-
ant among all ARID proteins found within the mammalian SWI/
SNF complexes, including ARID1b and ARID2 (10). Notably, all
known ARID proteins have a nonpolar residue (valine or isoleu-
cine) corresponding to this position (55).
Nonpolar amino acids typically stabilize proteins by sequester-
ing their side chains in hydrophobic environments. To gather mo-
lecular information about the critical V1068 residue, we simulated
the effect of the valine-to-glycine substitution in V1068G using a
computational algorithm called simplicial neighborhood analysis
of protein packing (SNAPP), which is useful for estimating how
mutational changes in hydrophobic residues affect protein stabil-
ity (46, 56–58). In general, a mutation that lowers the total SNAPP
score negatively contributes to protein stability (56). We calcu-
lated the SNAPP scores for all eight 120-amino-acid conformers
derived from the previously reported nuclear magnetic resonance
(NMR) solution structure of the ARID domain (hARID) of Homo
sapiens ARID1a (Protein Data Bank [PDB] code 1RYU) (59). Our
analysis yielded an average SNAPP score of 268.7 for all wild-type
hARID conformers. By substituting valine for a glycine residue,
this average score is reduced by 2.8 log-likelihood units, suggest-
ing a reduction in thermodynamic stability. Scoring of individual
residue contacts within the V1068 side chain contact neighbor-
hood indicated that this negative difference is attributable to the
effect of the glycine on the collapse of a hydrophobic pocket cre-
ated by side chains emanating from a multi--helical bundle con-
sisting of -helices 2 to 5 (H2 to H5) (Fig. 4B). Of the 14 amino
acids conserved throughout all Dri/BRIGHT minimal ARIDs,
V1068 and two other nonpolar residues (V1059 and Y1097) con-
stitute this hydrophobic residue cluster, whereas the other two
residues found in this region (L1077 and K1094) show conserva-
tive changes across most Dri/BRIGHT ARIDs (Fig. 4A, blue bold-
face, and B, inset). Consistent with nonpolar side chain sequester-
ing tendencies, the single polar side chain identified in this motif,
K1094, is oriented toward the edge of this cluster, while the ali-
phatic valine and leucine side chains (V1059, V1068, and L1077)
and the bulky aromatic ring of tyrosine 1097 are sequestered to-
ward its center (Fig. 4B). We predict that the V1068G mutation
disrupts favorable van der Waals contacts within this pocket re-
gion, leading to ARID domain instability and diminished DNA
binding potentials.
To test this hypothesis, single-component saturating electro-
phoretic mobility shift assays (ssEMSAs) were performed using
bacterially expressed GST fusion protein fragments containing ei-
ther a wild-type or mutant (V ¡ G) ARID domain from human
ARID1a (GST-hARID) (Fig. 2). In ssEMSAs, the apparent Kd (dis-
sociation constant), or Kapp, equals the protein concentration for
which 50% of the DNA is bound when the DNA probe concen-
tration is limiting. Binding isotherms were estimated from reac-
tion mixtures containing titrated amounts of protein and limiting
amounts (50 pM) of the radiolabeled dri.16 probe (16). As shown
in Fig. 5A and C, saturating amounts of wild-type GST-hARID
protein are capable of binding subsaturating amounts of DNA.
FIG 4 Structural implications of the conserved valine 1068 residue. (A) Clustal alignment of minimal ARID domains from M. musculus (Mm) ARID1a/BAF250a
aligned with similar regions from D. melanogaster (Dm) Osa and S. cerevisiae (Sc) SWI1 ARID subunits, as well as D. melanogaster Retn/Dri/Bright and M.
musculus ARID3a/BRIGHT proteins. The mutated valine 1068 residue (red) is highlighted in yellow. (B, left) PyMol rendition of all eight ARID domain NMR
conformers (PDB code 1RYU) for the ARID domain structure of H. sapiens ARID1a. -Helices are depicted in red. V1068 is located in -helix 3. (B, right)
Close-up view of the V1068 side chain contact neighborhood. Favorable, nearest-neighbor V1068, V1059, Y1097, L1077, and K1094 (blue boldface in panel A)
side chain interactions form a hydrophobic pocket in the center of a multi--helical bundle (H2 to H5).
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Curve fitting calculated a Kapp of 92.2 nM for the wild-type GST-
hARID protein fragment (Fig. 5C). However, even high concen-
trations (2 M) of mutant protein fragments carrying the valine-
to-glycine substitution are not capable of binding DNA (Fig. 5B
and C). Similar results were observed in reaction mixtures con-
taining saturating amounts (1 M) of wild-type or mutant GST-
hARID protein fragments and an alternate DNA probe or reaction
buffer (data not shown). Thus, the V1068G substitution causes a
severe reduction in ARID1a-DNA interactions.
Since the residues comprising the ARID hydrophobic pocket
show conservation among Dri/BRIGHT ARID proteins, we next
wanted to determine if this substitution would also abrogate the
DNA binding potentials of a functionally unrelated, sequence-
specific ARID domain within this clade. Similar ssEMSAs were
performed using a GST fusion protein fragment encompassing
the Drosophila Retn/Dri ARID domain (GST-DriARID) and a ra-
diolabeled probe (dri.16) containing its cognate binding site (16,
30). Consistent with previously reported binding affinity mea-
surements, wild-type GST-DriARID fragments are capable of
binding DNA with a Kapp of 50.2 nM (Fig. 5D and F) (32). How-
ever, mutant GST-DriARID fragments carrying the valine-to-gly-
cine substitution are not capable of saturation binding at protein
concentrations greater than the Kapp of the wild-type fragment.
Likewise, since less than 20% of the free DNA is bound in reaction
mixtures containing micromolar amounts of mutant GST-Dri-
ARID, the Kapp for this fragment could not be estimated (Fig. 5E
and F). Taken together, these data strongly suggest that a central
hydrophobic pocket formed by a multi--helical bundle within
the ARID domain is required for both non-sequence- and se-
quence-specific DNA interactions.
Loss of ARID1a-DNA interactions reduces BAF-A affinity
for nucleosomes. In addition to primary recruitment by tran-
scription factors, it has been proposed that the full binding capac-
ity of SWI/SNF for its nucleosomal substrate requires the summa-
tion of multiple sequence-nonspecific subunit-chromatin
interaction surfaces (60). To test whether impaired ARID1a-DNA
interactions reduce BAF-A binding affinity for nucleosomes, we
performed competitive nucleosome pulldown assays using na-
FIG 5 The V1068G mutation leads to loss of DNA binding. (A and B) Single-component saturating EMSAs (ssEMSAs) using titrated amounts of wild-type (wt)
or mutant (mut; V ¡ G) recombinant protein fragments containing the non-sequence-specific ARID domain of H. sapiens (Hs) ARID1a. (D and E) Similar
ssEMSAs using titrated amounts of wild-type or mutant (V ¡ G) recombinant protein fragments containing the sequence-specific ARID domain of D.
melanogaster Retn/Dri/Bright. Subsaturating amounts of the dri.16 probe (50 pM) were used in each DNA binding reaction. (C and F) Fractional occupancies
were calculated from band densitometry measurements and plotted versus log protein concentrations. Blue dotted lines in panels C and F represent curves fitted
to EMSA results using Kaleidagraph software.
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tively purified wild-type or mutant BAF-A complexes. Saturating
amounts of immobilized (on beads) complexes were incubated
with limiting amounts of radiolabeled nucleosomes in reaction
mixtures containing titrated amounts of cold competitor DNA
(Fig. 6A). Under competitive binding conditions, differences in
the amount of nucleosome bound correlates with differences in
the relative binding affinities of the complex. In reaction mixtures
containing no competitor DNA, nucleosome binding by mutant
BAF-A complexes was comparable to that of the wild type (Fig. 6A
and B). However, a significant reduction in mutant BAF-A bind-
ing affinity was observed in reaction mixtures containing increas-
ing amounts of competitor DNA, with approximately 1.5-fold less
nucleosomal substrate bound to mutant complexes at competitor
DNA concentrations as low as 3.1 ng (Fig. 6A and B). No binding
was observed in reaction mixtures containing mock-purified sam-
ples (Fig. 6A and B). Altogether, these data strongly suggest that a
severe reduction in ARID1a-DNA interactions leads to a moder-
ate decrease in BAF-A affinity for nucleosomes, which would be
consistent with a role for the ARID domain in contributing to
some, but not all, SWI/SNF subunit-chromatin interactions.
The ARID domain of ARID1a is required for repressive
BAF-A associations at THBS1. To determine if the V1068G lesion
augments ARID1a occupancy at gene promoters, we performed
chromatin immunoprecipitation (ChIP) assays on formaldehyde-
cross-linked chromatin from exponentially growing wild-type
and mutant Arid1aV1068G/V1068G MEFs. We decided to use MEFs in
these experiments because they can be efficiently cultured at a
scale amenable to biochemical fractionation and because they can
easily be isolated from embryos prior to E10.0. The following set of
putative ARID1a target genes was chosen because they are widely
expressed throughout the embryo and because they are targets of
BRG1 or BRM: THBS1, ADAMTS1, and CRABP1 (61–63). Two
unlinked promoter control elements from a constitutive
(GAPDH) or silent (INSULIN-1 or INS-1) gene were used as neg-
ative genomic controls (Fig. 7A). ARID1a was enriched over these
control regions at all three putative targets in wild-type MEFs
(Fig. 7A). In Arid1aV1068G/V1068G MEFs, mutant ARID1a occu-
pancy was reduced to nearly background levels at all target sites
examined, indicating that this mutant protein does not efficiently
bind chromatin (Fig. 7A). This reduction also correlates with con-
current changes in target gene expression (Fig. 7B).
Since the V1068G mutation in ARID1a lowers BAF-A affinity
for nucleosomes and since ARID1a occupancy is reduced in mu-
tant cells, we reasoned that mutant BAF-A occupancy would also
be affected by this mutation. To test this idea, we performed ad-
ditional subunit-specific ChIP experiments to determine if pro-
moter occupancy by the BAF-A complex is dependent on the
ARID domain. Among the ARID1a target genes examined,
THBS1 emerged as a good candidate for these experiments be-
cause transcriptional control elements within 2.8 kb upstream of
its promoter have been extensively characterized in mouse embry-
onic fibroblast cell lines (45, 64, 65). Thus, THBS1 served as a
model BAF-A target gene to further probe ARID domain func-
tion. We chose a ChIP-scanning approach to narrow regions of
SWI/SNF enrichment across a 4-kb interval spanning this pro-
moter fragment, largely focusing on genomic “landmarks” such as
conserved regions or transcription start sites (Fig. 8A). BAF-A
complexes are known to incorporate either BRG1 or BRM, and
BRG1 incorporates into PBAF complexes containing ARID2.
Therefore, to adequately survey all potential SWI/SNF complex
configurations within this interval, we performed ChIP using an-
tibodies that recognize all of the mammalian ARID subunits,
ARID1a, ARID1b, and ARID2, as well as the catalytic subunits,
BRG1 and BRM. We also included the core subunit INI1/SNF5,
which is common to all mammalian SWI/SNF complexes. A cis-
linked and nonconserved intergenic region located approximately
20 kb downstream of the THBS1 transcription start site (TSS) and
the promoter control elements, GAPDH and INS-1, were used as
negative genomic controls.
In wild-type MEFs, ARID1a enrichment was detected at a con-
served upstream promoter element and at a downstream genic
region located at kb 1.0 (Fig. 8B). ARID1a enrichment is coin-
FIG 6 Loss of sequence-nonspecific ARID1a-DNA interactions reduces BAF-A affinity for nucleosomes. (A) Saturating amounts of immobilized wild-type or
mutant BAF-A complexes were incubated with limiting amounts of radiolabeled mononucleosomes in reaction mixtures containing increasing amounts of cold
competitor DNA, and then the beads were subjected to a pulldown and washing. Mock-purified fractions from wild-type or mutant cells were used as negative
controls. (B) Graph depicts the average scintillation counts measured from independent binding reactions. The numbers above the graphical columns denote the
fold difference in average scintillation counts of the wild type compared to those of the mutant. Significant differences were calculated using a two-tailed Student
t test (*, P  0.05).
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cident with BRM and INI1/SNF5 enrichment at these sites in wild-
type cells (Fig. 8E and G). In Arid1aV1068G/V1068G MEFs, BRM-
containing BAF-A complexes were depleted from these sites, as
indicated by the reduction in ARID1a and BRM occupancy (Fig.
8B and E). INI1/SNF5 was also depleted from the upstream site,
but its enrichment remained unaltered at the downstream kb 1.0
site in these cells (Fig. 8G). We detected BRG1 and the PBAF-specific
ARID subunit, ARID2, at this downstream site only in mutant cells,
which accounts for INI1/SNF5 occupancy at this site (Fig. 8C and F).
We did not detect ARID1b enrichment at these sites in either wild-
type or Arid1aV1068G/V1068G cells (Fig. 8D). We conclude that loss of
ARID-DNA interactions in V1068G mutants perturbs proper BAF-A
associations at THBS1, and these losses can influence chromatin as-
sociations by additional SWI/SNF complexes.
To determine if these changes in promoter occupancy corre-
lated with concurrent changes in THBS1 expression, we profiled
THBS1 expression in MEFs or embryos. In Arid1aV1068G/V1068G
MEFs, THBS1 was upregulated by quantitative RT-PCR (qRT-
PCR), compared to wild-type levels (Fig. 8J). THBS1 protein lev-
els from E9.5 whole-embryo lysates (triplicate pooled) for all ge-
notypic classes were examined by Western blotting. THBS1
protein levels were increased in E9.5 Arid1aV1068G/V1068G versus
wild-type embryos, which is consistent with our qRT-PCR results
(Fig. 8I). We also detected a slight increase in THBS1 protein in
Arid1aV1068G/ embryos (Fig. 8I). We further verified THBS1 up-
regulation by Western blotting and direct immunostaining of tis-
sue sections from E10.5 Arid1aV1068G/V1068G versus wild-type em-
bryos (data not shown). RNA polymerase II (Pol II) occupancy
was also increased over the TSS and transcribed, genic region
(kb 1) of THBS1 in mutant MEFs, suggesting that ARID-depen-
dent regulation of THBS1 by BAF-A is likely occurring at the level
of transcriptional repression (Fig. 8H).
To further explore this idea, we transfected wild-type and
Arid1aV1068G/V1068G MEFs with small interfering RNAs (siRNAs)
that target BRG1 or BRM. In wild-type MEFs, siRNA depletion of
BRM, but not BRG1, led to THBS1 upregulation, which is consis-
tent with repression by BRM-containing, BAF-A complexes (Fig.
8J). In contrast, BRG1 depletion in mutant cells resulted in THBS1
downregulation, suggesting that PBAF occupancy at the down-
stream site likely contributes to the transcriptional upregulation
we observed in mutant cells (Fig. 8J). These results further suggest
that BRM-containing BAF-A complexes directly repress THBS1
transcription in an ARID-dependent manner.
To test this model, we cotransfected increasing amounts of
wild-type or mutant (V1068G) HA-tagged mouse ARID1a cDNA
expression plasmids with a mouse THBS1 2.8 kb promoter-
luciferase reporter plasmid into NIH 3T3 cells. Overexpression of
wild-type ARID1a repressed the THBS1 2.8 kb promoter at plas-
mid concentrations at or above 0.25 g (Fig. 8K). However, this
level of repression was not observed in cells transfected with sim-
ilar amounts of mutant ARID1a cDNA (Fig. 8K). To determine if
ARID1a directly regulates this promoter in a manner that is con-
sistent with BAF-A binding to the upstream conserved element,
we performed a separate set of cotransfections using a minimal
THBS1 0.48 kb promoter-luciferase fragment and 0.25 g of
wild-type or mutant ARID1a expression plasmids. As expected,
ARID1a overexpression repressed the THBS1 2.8 kb promoter
fragment in an ARID domain-dependent manner, whereas nei-
ther wild-type nor mutant ARID1a had an effect on the activity of
the THBS1 0.48 kb fragment in parallel assays (Fig. 8L). These
data strongly suggest that the upstream element is a site of THBS1
promoter repression by BAF-A. ChIP and expression data for
THBS1 are summarized in Fig. 8M. Taken together, these data
demonstrate that the ARID domain of ARID1a is both necessary
and sufficient for repressive BRM-containing BAF-A associations
at THBS1.
DISCUSSION
In this study, we report the molecular and phenotypic character-
ization of an ENU-induced point mutation within the ARID DNA
FIG 7 Loss of DNA binding correlates with reduced promoter occupancy and concurrent changes in SWI/SNF target gene expression. (A) Formaldehyde-cross-
linked chromatin from wild-type and Arid1aV1068G/V1068G MEFs was immunoprecipitated using an ARID1a-specific antibody. DNA was amplified by quantita-
tive PCR to determine if mutant ARID1a occupancy was reduced at known SWI/SNF target gene promoters (THBS1, ADAMTS1, and CRABP1). Promoter
control elements for a constitutive (GAPDH) or silent (INS-1) gene were used as negative genomic controls. Data were plotted as the percentage of total input or
chromatin bound. (B) cDNA synthesized from RNA isolated from wild-type or Arid1aV1068G/V1068G MEFs was used in a quantitative PCR to examine target gene
expression differences. Error bars in both panels represent the SEMs, and significant differences between the wild type and mutant were calculated using a
two-tailed Student t test (*, P  0.05).
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binding domain of ARID1a. This single amino acid substitution
abrogates the DNA binding capacities of ARID1a but does not
influence ARID1a protein levels, nor does it compromise the in-
tegrity or the core catalytic properties of the BAF-A complex. Loss
of ARID1a-DNA binding led to a convergence of heart and vas-
cular defects in mutant embryos, and the sum of defects culmi-
nated in ischemic arrest around midgestation. Our data indicate
that the function of the SWI/SNF ARID domain is to facilitate
complex binding to target gene promoters. Genetic evidence sup-
porting such a role has remained nonexistent until now.
The importance of valine 1068 in both sequence-dependent
and -independent ARID-DNA interactions has been unexplored
because this residue does not contact DNA (32, 59). Our data
indicate that this highly conserved, nonpolar amino acid specifi-
cally influences ARID domain stability and/or conformation
through hydrophobic side chain packing although we cannot rule
out the possibility that a yet untested protein-protein interaction
is also perturbed. The functional significance of these hydropho-
bic interactions can be applied to most ARID proteins found in
higher eukaryotes because they all have nonpolar residues corre-
sponding to ARID1a positions 1059, 1068, 1077, and 1097 within
this packing motif (32, 55, 59). In addition, at least one human
cancer cell line (MDA-MB-361) has a valine-to-glycine substitu-
tion in amino acid 1059 (1058 in human) in ARID1a (66). We
predict that this substitution also perturbs the ARID domain hy-
drophobic pocket, leading to loss of DNA binding. This highlights
how protein structure-function-based approaches in the mouse
can be used to predict the functional impact of missense muta-
tions in humans.
SWI/SNF ARIDs are predicted to bind within the major
groove, but they have lost the ability to bind specific bases within
this region because the major groove-interacting, helix-turn-he-
lix-like (H4-L2-H5) subdomain has been modified, and amino
acids found at base-specific contact positions within this sub-
domain have diverged (32, 59). Less is known about how the flex-
ible, minor groove- and phosphate backbone-interacting L1 loop
and C terminus or the divergent extended ARID regions influence
binding affinity and/or sequence preference. However, these in-
teraction surfaces are also involved in DNA recognition because
mutations in key major groove contact residues do not completely
abolish DNA binding (10). The V1068G mutation reduced the
DNA binding capacities of ARID fragments from Dri/BRIGHT
and ARID1a proteins to nonphysiological levels. Therefore, this
mutation likely perturbs multiple DNA interaction surfaces
within the ARID domain, which is consistent with a severe reduc-
tion in ARID domain function.
Although SWI/SNF ARIDs lack the major groove consensus
binding convention used by most sequence-specific binding pro-
teins, they may show increased binding affinity for a yet undeter-
mined DNA sequence or higher-order DNA structure, or their
recognition of DNA may be facilitated through the exploitation of
sequence-dependent DNA deformability. Interactions like these
may be driven, in part, by minor groove interactions, which are
often accompanied by DNA bending. At least one example of
ARID-induced DNA bending has been reported (67). Additional,
high-resolution binding studies using full-length ARID subunits
or approaches based on ChIP with high-throughput sequencing
(ChIP-seq) may provide additional information.
A previous report has identified an upstream element between
kb 1.3 and 1.1 of the mouse THBS1 promoter that is strongly
repressive in NIH 3T3 cells (65). Consistent with these findings,
our data suggest that ARID domain-dependent BAF-A enrich-
ment within this element is necessary for THBS1 repression. Ad-
ditional sequences within 2.8 kb upstream of the THBS1 promoter
likely contain activating elements because the basal activity of this
fragment is greater than that of the minimal THBS1 0.48 kb
fragment tested, despite having the upstream repressive element.
Moreover, THBS1 transcripts and protein were detected in wild-
type cells and embryos, respectively. We speculate that BAF-A
activity at the upstream element may buffer the transcription out-
put of THBS1, yet “prime” this locus for rapid induction in re-
sponse to external stimuli, which would be consistent with its role
as an immediate-early response gene (68, 69). The identification
of factor binding sites that are necessary for BAF-A-mediated re-
pression of THBS1 promoter activity or stimuli required to relieve
this repression may allow us to further explore these possibilities.
Unexpectedly, we observed an ARID-dependent switch from a
BAF-A to a PBAF configuration at a separate, and previously un-
characterized, downstream site located within the transcribed re-
gion (intron 2) of THBS1. Indeed, our data suggest that BAF-A
binding to this downstream site may also regulate THBS1 activity.
Recently, a similar switch from BAF-A to PBAF was observed on a
single nucleosome following phorbol myristate acetate (PMA)
stimulation of the HIV long terminal repeat (LTR) (70). At the
THBS1 downstream site, we speculate that, similar to what has
been proposed for the HIV LTR, repressive nucleosome position-
ing by BAF-A may act as a barrier to PBAF recruitment, perhaps
limiting THBS1 elongation rates. Although it is still unclear
FIG 8 The ARID domain of ARID1a is required for BAF-A occupancy at THBS1. (A) Mouse/human VISTA alignment of the THBS1 promoter and 5=
transcribed region. Salmon-colored peaks denote evolutionarily conserved regions, whereas lavender peaks denote exons. The locations of ChIP amplicons
within this interval are plotted. (B to H) Formaldehyde-cross-linked chromatin from wild-type and Arid1aV1068G/V1068G MEFs was immunoprecipitated with
ARID1a, ARID1b, ARID2, BRG1, BRM, INI1/SNF5, or Pol II antibodies. DNA was amplified by quantitative PCR to determine if loss of ARID-DNA binding
leads to changes in BAF-A occupancy across THBS1. An intergenic, nonconserved downstream region (located at approximately kb 20) and two unlinked
promoter control elements (GAPDH and INS-1) were used as negative genomic controls. Data were plotted as the percentage of total input or chromatin bound.
(I) Whole-embryo protein lysates from triplicate pooled samples were used to examine THBS1 protein (reduced, monomeric form) expression differences by
Western blotting. An overexposed image of the Western blot was also included to further emphasize these expression differences. The constitutive nuclear matrix
protein, nucleolin, was used as a loading control. (J) cDNA synthesized from RNA isolated from wild-type or Arid1aV1068G/V1068G MEFs was used in a quantitative
PCR to examine THBS1 expression differences following transfection with mock (nontargeting control), BRG1, or BRM siRNA. (K) Normalized luciferase
activity of the THBS1 2.8 kb promoter-luciferase fragment cotransfected with 0.05 to 0.5 g of wild-type or mutant HA-mARID1a expression plasmids into
NIH 3T3 cells. Cells cotransfected with the empty luciferase vector (luc) or THBS1 2.8 kb promoter-luciferase fragment and with empty pcDNA expression
plasmids served as negative and positive controls, respectively. (L) Normalized luciferase activity of THBS1 2.8 kb and 0.48 kb promoter-luciferase reporter
plasmids cotransfected with 0.25 g of pcDNA only () or wild-type or mutant HA-mARID1a expression plasmids. Empty luciferase reporter plasmid was used
as a negative control. (M) Summary model of ChIP and expression data. Error bars in panels B to H and in panel J represent the SEMs. Error bars in panels K and
L represent the standard deviations. Significant differences were calculated using a two-tailed Student t test (*, P  0.05).
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whether PBAF can be recruited to this site in wild-type cells fol-
lowing THBS1 stimulation or if the switch we observed occurs on
a single nucleosome, our data would also suggest that PBAF activ-
ity at this site contributes to the THBS1 upregulation we observed.
Such antagonism may be an important regulatory step if the re-
modeling activity of one complex modulates the activity or re-
cruitment of another, especially considering that two or more dis-
tinct complexes are often present in the same cell. This premise
may integrate multiple chromatin remodelers into the regulatory
decisions at a given locus. More data are needed to determine if
complex switching or antagonism is a frequent event or if it is
implicated in a particular transcriptional regulatory process.
The hypomorphic phenotypes observed in Arid1aV1068G/V1068G
embryos indicate that some BAF-A activities are maintained fol-
lowing a severe reduction in ARID domain function. These partial
loss-of-function phenotypes would be expected if mutant ARID1a
had some residual binding activity in vivo or if there were partial
redundancy between the ARID domain and other recruitment
factors at select sites. Alternatively, BAF-A interactions with RNA
polymerase II or other macromolecular complexes may circum-
vent the need for this targeting domain in additional processes
that require SWI/SNF chromatin remodeling activities (71, 72).
The phenotypic severity of the V1068G mutation parallels muta-
tions in yeast SWI/SNF that remove ARID or bromodomain func-
tion as these domains are not required for full complex activity in
vivo (53, 73). These rather limited targeting domain requirements
suggest that multiple factors influence SWI/SNF recruitment in
vivo.
The ARID domain is not the first target site-indiscriminate
chromatin interaction domain implicated in SWI/SNF recruit-
ment processes. For example, acetylated histone tails can increase
SWI/SNF binding affinity for nucleosomes in a bromodomain-
dependent manner, and this bromodomain-acetyl-histone H3 tail
interaction is required for promoter occupancy by SWI/SNF (73,
74). These findings suggest that subunit interactions with se-
quence-specific transcription factors alone are not sufficient for
SWI/SNF recruitment and that proper SWI/SNF associations with
chromatin require intrinsic ARID-DNA and subunit-histone in-
teractions. Additional site-indiscriminate subunit-DNA or sub-
unit-histone interaction modules within SWI/SNF may perform
similar roles, and their use, in combination, may further enhance
recruitment or guide target site selection. Indeed, the moderate
differences we observed in the relative nucleosome binding affin-
ities for wild-type versus ARID-defective BAF-A complexes are
similar to the differences observed for bromodomain-dependent
SWI/SNF binding to acetylated versus unmodified histone H3
tails, suggesting that the combined effect of multiple subunit-
chromatin interaction surfaces would titrate the binding affinities
well above what would be expected from a single point of interac-
tion (74). These interactions may also influence the residence time
or off rate of the complex, which would stabilize site-specific as-
sociations (73). It is possible that ARID-DNA interactions with
chromatin also induce conformational or allosteric changes in the
complex, perhaps in a manner similar to the separable role pro-
posed for bromodomain-acetyl-histone H3 tail interactions in
H2A/H2B dimer displacement (74). Nonetheless, our data sup-
port the idea that cooperative interactions among intrinsic sub-
unit-chromatin interaction domains and sequence-specific tran-
scription factors drive SWI/SNF recruitment in vivo. Such
cooperativity may allow the complex, or complex-associated tran-
scription factor, interrogate low-affinity, nucleosome-bound sites
while at the same time confer combinatorial control of target
genes through differential subunit and transcription factor usage
(60). These concepts are crucial for understanding how remodel-
ers or other chromatin-modifying enzymes recognize and bind
their naturally repressive substrates.
The high prevalence of inactivating ARID1a mutations in
ovarian clear cell and endometrioid tumors strongly suggests that
loss of ARID1a contributes to the etiology of ovarian cancer (24,
25). Several of these mutations occur only in the heterozygous
state, supporting the known gene dose-dependent requirements
of ARID1a in the mouse (23). Whether Arid1aV1068G/ mice are
more susceptible to ovarian tumors will require additional exper-
iments. Nonetheless, we are optimistic that this mutant allele will
advance our understanding of this disease.
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